In addition there are a number of other ongoing clinical trials assessing the efficacy and tolerability of new indications or label extensions for products like SUBA-itraconazole, FABIOR
, LEXETTE and SORILUX, some of which are investigator initiated studies.
and Sorilux will be marketed through Mayne Pharma's Specialty Brands Division and existing sales team.
Fabior (tazarotene) Foam, 0.1% is a patent-protected topical product indicated for the treatment of acne, the largest dermatology indication in the US affecting up to 50 million Americans every year.
Both Fabior and Sorilux will be marketed through Mayne Pharmas Specialty Brands Division and existing sales team.
M2 EQUITYBITES-May 14, 2012-Stiefela[euro](tm)s Fabior Foam receives US FDA approval(C)2012 M2 COMMUNICATIONS http://www.m2.com
Dermatology and skin science company Stiefel, a division of GlaxoSmithKline plc (NYSE:GSK) (LSE:GSK.L), announced on Friday that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam 0.1%.